TABLE 1.
ST | Allele no. for:
|
No. of isolates with ST | Production system(s)a | Resistance profileb | ||||||
---|---|---|---|---|---|---|---|---|---|---|
aspA | glnA | gltA | glyA | pgm | tkt | uncA | ||||
825 | 33 | 39 | 30 | 82 | 113 | 47 | 17 | 4 | ABF (F), conv (F) | E, T, ChET |
828 | 33 | 39 | 30 | 82 | 104 | 43 | 17 | 2 | ABF (S) | Pansusceptible, T |
854 | 33 | 38 | 30 | 82 | 104 | 43 | 17 | 7 | ABF (F), conv (F, S) | E, T, ET |
887 | 33 | 38 | 30 | 82 | 104 | 85 | 68 | 4 | Conv (S) | T, ChET, ChEGNaT |
890 | 33 | 38 | 30 | 82 | 104 | 35 | 36 | 5 | ABF (F, S), conv (F, S) | T, ET, NaT, ChET |
1055 | 33 | 39 | 30 | 82 | 104 | 47 | 17 | 1 | ABF (F) | CENaT |
1056 | 33 | 39 | 30 | 82 | 104 | 43 | 36 | 2 | ABF (S), conv (F) | E, ET |
1058 | 33 | 39 | 30 | 82 | 104 | 35 | 17 | 1 | ABF (S) | Pansusceptible |
1059 | 33 | 153 | 30 | 82 | 104 | 35 | 17 | 1 | Conv (F) | ET |
1068 | 33 | 39 | 30 | 78 | 104 | 43 | 17 | 2 | ABF (F), conv (S) | NAL, E |
1096 | 33 | 38 | 30 | 82 | 104 | 35 | 17 | 9 | ABF (F, S), conv (F, S) | E, ET, ChET, ChEG, CENaT, ENaT |
1102 | 33 | 38 | 30 | 82 | 152 | 173 | 68 | 1 | ABF (F) | E |
1112 | 33 | 39 | 30 | 82 | 104 | 43 | 68 | 7 | ABF (F, S), conv (F) | Pansusceptible, E, T, ET, NaT, ChET |
1113 | 33 | 38 | 30 | 78 | 104 | 35 | 17 | 1 | ABF (S) | T |
1123 | 53 | 38 | 44 | 82 | 118 | 35 | 36 | 6 | ABF (F), conv (S) | Pansusceptible, T, ET, ChENaT |
1130 | 33 | 38 | 30 | 82 | 104 | 43 | 68 | 2 | ABF (F), conv (S) | T, ET |
1134 | 33 | 38 | 30 | 82 | 104 | 173 | 68 | 5 | ABF (F), conv (F) | Pansusceptible, NaT, ChET |
1142 | 33 | 153 | 30 | 82 | 104 | 43 | 36 | 1 | Conv (S) | T |
1177 | 33 | 38 | 30 | 82 | 104 | 85 | 17 | 3 | ABF (F), conv (F) | ENa |
1185 | 33 | 38 | 44 | 82 | 104 | 35 | 36 | 1 | ABF (S) | ET |
1200 | 53 | 38 | 30 | 82 | 118 | 35 | 36 | 1 | ABF (F) | T |
1413 | 33 | 38 | 30 | 82 | 104 | 117 | 17 | 9 | Conv (F) | T, ChET, CENaT |
1414 | 33 | 39 | 37 | 82 | 104 | 43 | 68 | 2 | ABF (F) | Pansusceptible, ET |
1415 | 33 | 39 | 47 | 82 | 104 | 43 | 36 | 1 | ABF (S) | E |
1417 | 33 | 39 | 44 | 82 | 104 | 35 | 36 | 3 | Conv (F, S) | E, ET |
1419 | 33 | 38 | 46 | 82 | 104 | 117 | 17 | 1 | Conv (F) | CENaT |
1421 | 33 | 38 | 44 | 82 | 104 | 117 | 36 | 1 | Conv (F) | E |
1422 | 33 | 38 | 46 | 82 | 104 | 173 | 17 | 1 | Conv (F) | ET |
1423 | 33 | 39 | 46 | 82 | 104 | 47 | 17 | 1 | Conv (F) | ET |
1424 | 33 | 39 | 132 | 82 | 104 | 44 | 17 | 1 | ABF (F) | ChNaT |
1426 | 53 | 38 | 30 | 81 | 118 | 85 | 36 | 1 | ABF (F) | Pansusceptible |
1428 | 53 | 38 | 30 | 81 | 118 | 43 | 36 | 4 | Conv (S) | E, ET |
1429 | 33 | 39 | 44 | 82 | 189 | 35 | 36 | 1 | Conv (F) | ET |
1436 | 33 | 39 | 44 | 82 | 104 | 44 | 17 | 1 | ABF (F) | T |
1437 | 33 | 39 | 46 | 82 | 104 | 43 | 68 | 1 | ABF (F) | ENaT |
1438 | 33 | 153 | 30 | 82 | 104 | 44 | 17 | 3 | ABF (F), conv (F, S) | ET, CNaT |
1439 | 33 | 38 | 30 | 82 | 104 | 173 | 17 | 2 | Conv (F) | ENaT |
1441 | 33 | 38 | 37 | 82 | 104 | 117 | 17 | 1 | Conv (F) | CENaT |
1442 | 33 | 38 | 132 | 82 | 104 | 85 | 17 | 1 | Conv (F) | ET |
1444 | 33 | 39 | 30 | 82 | 104 | 171 | 17 | 1 | ABF (F) | E |
1445 | 33 | 39 | 30 | 82 | 104 | 85 | 17 | 4 | ABF (S), conv (F) | Pansusceptible, T, ET |
1446 | 33 | 38 | 30 | 82 | 118 | 35 | 17 | 2 | ABF (F) | ET |
1449 | 33 | 38 | 37 | 78 | 104 | 35 | 17 | 1 | ABF (S) | T |
1450 | 53 | 39 | 44 | 82 | 104 | 35 | 36 | 4 | ABF (S) | Pansusceptible, Na, T, ET |
1452 | 33 | 39 | 46 | 82 | 104 | 44 | 17 | 2 | ABF (F) | Pansusceptible, CNaT |
1455 | 33 | 38 | 37 | 82 | 104 | 85 | 68 | 1 | Conv (S) | T |
1463 | 33 | 153 | 30 | 82 | 104 | 85 | 17 | 1 | ABF (F) | NaT |
1464 | 33 | 39 | 30 | 82 | 104 | 117 | 17 | 1 | Conv (F) | EGT |
1465 | 33 | 39 | 30 | 82 | 113 | 117 | 17 | 1 | Conv (F) | EGT |
ABF (F), antimicrobial-free production system (finishing farm); ABF (S), antimicrobial-free production system (slaughter); conv (F), conventional production system (finishing farm); conv (S), conventional production system (slaughter).
Ch, chloramphenicol; C, ciprofloxacin; E, erythromycin; G, gentamicin; Na, nalidixic acid; T, tetracycline.